EPHA2 and pheochromocytoma-paraganglioma: Similarly, elevated EphA2 expression indicated a poor prognosis for patients with colon adenocarcinoma (COAD), diffuse large B-cell lymphoma (DLBC), low-grade glioma (LGG), and pancreatic adenocarcinoma (PAAD), yet correlated with higher survival rates in those with kidney chromophobe (KICH) and pheochromocytoma and paraganglioma (PCPG).